Read more about BIAL’s expansion.
BIAL enters the US and acquires “promising” Parkinson’s disease programmes
Author: Simge Eva DoganPublished: 8 October 2020
Prep: Cook: Serves:
Portugal-based pharmaceutical company BIAL has launched a new research centre, BIAL Biotech, in Massachusetts, US, which will focus on genetically defined Parkinson’s disease.
BIAL has also announced that it has acquired the Parkinson’s disease research programmes of Lysosomal Therapeutics Inc, as well as its research and development team and clinical programme for LTI-291 – a therapy designed to treat a genetic form of the condition.
António Portela, executive president of BIAL, said: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programmes from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide.
“The development of this new research centre in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine.”
Lead image: research and development department at BIAL
For more information on the latest Parkinson’s disease research please visit the EPDA website.
Share this story
I’ve got Parkinson’s and cancer: Billy Connolly’s tear-jerking appeal
Viewers praise “brilliant” Billy Connolly charity videoREAD MORE
Watch: Judas Priest guitarist Glenn Tipton returns to stage after Parkinson’s diagnosis
The guitarist was back in action at a rock festival in SwedenREAD MORE
That moment the doc drops the P bomb
What it’s like to be diagnosed with Parkinson’s at 29 years oldREAD MORE